StockData
Evofem Biosciences, Inc. logo

Evofem Biosciences, Inc. (EVFM) stock analysis

EVFMOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 1/30
$0.01−0.00 (-10.00%)

Close on Oct 19, 2026Market cap $865.23KP/E –Yield –

StockData Score

Prices as of Nov 11, 2026How the score works

Value0Growth0Performance1Health0Dividend0

Weak1 of 30 checks passed

Evofem Biosciences passes 1 of the 30 checks behind our score; 21 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
0/6
Growth
0/6
Past performance
1/6
Financial health
0/6
Dividend
0/6

What stands out

  • Net margin above its 5-year average

    Net margin was -84.7% over the last twelve months, against a 5-year average of -540%.

What to watch

  • Revenue growing under 10% a year

    Revenue grew 6.2% a year over the last three fiscal years, short of the 10% we look for.

  • Interest not well covered

    Operating income covers interest expense -1.1 times; we look for at least 5.

  • Debt not well covered by cash flow

    Operating cash flow over the last twelve months equals -130% of total debt; we look for at least 20%.

  • Growing slower than the industry

    Revenue grew 4.5% over the last twelve months; the Drugs median is 8.0%.

Valuation0/6

  • P/E against its history

    Not enough price and earnings history to compare.

  • P/E against the industry

    Needs positive earnings and enough profitable companies in the industry.

  • EV/EBITDA against its history

    Needs positive EBITDA and price history.

  • P/B against the industry

    Needs positive book value.

  • Price against fair value

    We could not estimate a fair value: it needs at least two valuation methods with positive inputs.

  • Margin of safety

    Depends on the fair value estimate.

Growth0/6

  • Revenue growing under 10% a year

    Revenue grew 6.2% a year over the last three fiscal years, short of the 10% we look for.

  • EPS growth over 3 years

    Needs positive EPS three years ago and today.

  • Earnings acceleration

    Needs positive net income now, a year ago and five years ago.

  • Growing slower than the industry

    Revenue grew 4.5% over the last twelve months; the Drugs median is 8.0%.

  • Company guidance

    No outlook found in earnings releases from the last twelve months.

  • Gross margin slipping

    Gross margin was 75.5% over the last twelve months, against 79.7% a year earlier.

Past performance1/6

  • Return on equity

    Needs positive equity and five years of results.

  • Return on invested capital

    Needs operating income and invested capital.

  • Return on equity against the industry

    Needs positive equity.

  • Earnings over 5 years

    Needs positive net income five years ago and in the latest year.

  • Net margin above its 5-year average

    Net margin was -84.7% over the last twelve months, against a 5-year average of -540%.

  • Net margin below the industry

    Evofem Biosciences's net margin of -84.7% is below the Drugs median of -53.0%.

Financial health0/6

  • Debt level

    Needs debt and equity figures.

  • Debt trend

    Needs a balance sheet from five years ago with positive equity.

  • Debt not well covered by cash flow

    Operating cash flow over the last twelve months equals -130% of total debt; we look for at least 20%.

  • Interest not well covered

    Operating income covers interest expense -1.1 times; we look for at least 5.

  • Short-term assets don't cover short-term debts

    Current assets are 0.07 times current liabilities.

  • Bankruptcy risk (Altman Z)

    Needs market value, working capital and retained earnings.

Dividend0/6

  • No dividend

    Evofem Biosciences has not paid a dividend in the last twelve months.

  • Yield against Treasuries

    No dividend.

  • Yield against the market

    No dividend.

  • Dividend stability

    No dividend.

  • Earnings cover

    No dividend.

  • Cash-flow cover

    No dividend.

Scores of similar companies

Fair value

How we estimate it

We don't publish a fair value for Evofem Biosciences. It needs a US-dollar share price, at least two valuation methods with positive inputs (earnings, EBITDA, book value or sales) and, for companies with several share classes, classes that trade at the same price.

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

  • P/B at month end
  • Drugs median 2.3

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Margins

Share of revenue, fiscal years 2012 to 2025

Gross margin

77.1%+82.1 pts over 5 years

Operating margin

16.7%+23250.8 pts over 5 years

Net margin

1.9%+31909.8 pts over 5 years

See a number that looks wrong?